TEV-749 olanzapine LAI achieved 80% clinical stabilization in schizophrenia patients during the SOLARIS Phase 3 trial, with ...

FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 ...

CHMP recommends Ocrevus pediatric relapsing MS approval for children aged 10+, advancing toward European Commission ...

Velocity Clinical Research appoints Justin Starzyk as CEO to lead its 70+ research sites across the U.S. and Europe.

Teva study reveals healthcare providers prioritize tolerability and dosing convenience over efficacy when treating tardive dyskinesia in older patients.

New analysis suggests nonmelanoma skin cancer cases are 42% higher than official counts, with annual patient numbers reaching ...

Kamada confirms KedRAB supply meets surge in rabies inquiries. CDC reports 17% increase in rabies-related cases through ...

Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of ...

PEDMARK hearing protection met its primary endpoint in a Phase 2 study, showing significant ototoxicity reduction without ...

Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide ...

Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets ...

Boehringer Ingelheim's PED Essentials teaches patient organizations to collect and structure patient experience data for ...